Article

Combined assessment of<i>KRAS</i>mutational status and tumor size has no impact on prognosis in early-stage non-small cell lung cancer

2023-05-05

Abstract excerpt

<h4>Background</h4> KRAS mutation status, stage and tumor size at the time of diagnosis are well-established independent prognostic factors in non-small cell lung cancer (NSCLC). Here, we investigate the prognostic value of combining survival data on KRAS mutation status and tumor size in early-stage NSCLC. <h4>Methods</h4> We studied the combined impact of KRAS mutational status and tumor size on overall survival...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0a8dccf6-fc3a-5406-a306-d57e9dede825
DOI: 10.1101/2023.05.02.23289316

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Combined assessment of<i>KRAS</i>mutational status and tumor size has no impact on prognosis in early-stage non-small cell lung cancerDOI 10.1101/2023.05.02.23289316Read

A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer.Semantic proximity Read

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomesSemantic proximity Read

Clinical presentation and outcomes according to KRAS status in advanced non-small cell lung cancerSemantic proximity Read

Prognostic Impact of KRAS-TP53 Co-Mutations in Patients with Early-Stage Non-Small Cell Lung Cancer: A One Institution Retrospective AnalysisSemantic proximity Read

The prognostic value of Kirsten rat sarcoma viral oncogene homolog mutations in resected lung adenocarcinoma differs according to clinical features.Semantic proximity Read

KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.Semantic proximity Read

<i>KRAS</i>mutations impact clinical outcome in metastatic non-small cell lung cancerSemantic proximity Read

Characteristics and overall survival of patients with early-stage non-small cell lung cancer: A cohort study in Denmark.Semantic proximity Read

Differential Benefit of Immune Checkpoint Blockade by<i>KRAS</i>Mutation Status in Metastatic Lung Adenocarcinoma: Validation from an Extended Swedish CohortSemantic proximity Read

Real-World Evidence Study of Patients with KRAS-Mutated NSCLC in Finland.Semantic proximity Read

Outcomes After Surgical Resection of Early-stage Lung Adenocarcinomas With Epidermal Growth Factor Receptor Mutations.Semantic proximity Read

KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.Semantic proximity Read